Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability

Departments of Molecular Medicine, USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida 33613, USA.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.34). 09/2009; 29(39):12079-88. DOI: 10.1523/JNEUROSCI.3345-09.2009
Source: PubMed


Alzheimer's disease and other tauopathies have recently been clustered with a group of nervous system disorders termed protein misfolding diseases. The common element established between these disorders is their requirement for processing by the chaperone complex. It is now clear that the individual components of the chaperone system, such as Hsp70 and Hsp90, exist in an intricate signaling network that exerts pleiotropic effects on a host of substrates. Therefore, we have endeavored to identify new compounds that can specifically regulate individual components of the chaperone family. Here, we hypothesized that chemical manipulation of Hsp70 ATPase activity, a target that has not previously been pursued, could illuminate a new pathway toward chaperone-based therapies. Using a newly developed high-throughput screening system, we identified inhibitors and activators of Hsp70 enzymatic activity. Inhibitors led to rapid proteasome-dependent tau degradation in a cell-based model. Conversely, Hsp70 activators preserved tau levels in the same system. Hsp70 inhibition did not result in general protein degradation, nor did it induce a heat shock response. We also found that inhibiting Hsp70 ATPase activity after increasing its expression levels facilitated tau degradation at lower doses, suggesting that we can combine genetic and pharmacologic manipulation of Hsp70 to control the fate of bound substrates. Disease relevance of this strategy was further established when tau levels were rapidly and substantially reduced in brain tissue from tau transgenic mice. These findings reveal an entirely novel path toward therapeutic intervention of tauopathies by inhibition of the previously untargeted ATPase activity of Hsp70.

Download full-text


Available from: Aikaterini Rousaki,
  • Source
    • "Hsp70 inhibits tau aggregation by a mechanism involving preferential associations with soluble, monomeric, and prefibrillar oligomeric tau species and assists these combinations being degraded by the ubiquitin-proteasome and autophagy system (Figure 2) [93]. In a cell-based model, inhibiting Hsp70 ATPase activity after increasing its expression levels also facilitated tau degradation [94]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Heat shock proteins 70 and heat shock proteins 90 (Hsp70/90) have been implicated in many crucial steps of carcinogenesis: stabilizing oncogenic proteins, inhibiting programmed cell death and replicative senescence, induction of tumor angiogenesis, and activation of the invasion and metastasis. Plenty of cancer related proteins have the ability of regulating the expression of Hsp70/90 through heat shock factor 1. Cancer and Alzheimer's disease (AD) have plenty of overlapping regions in molecular genetics and cell biology associated with Hsp70/90. The Hsp70, as a protein stabilizer, has a cellular protection against neurodegeneration of the central nervous system, while Hsp90 promote neurodegenerative disorders indirectly through regulating the expression of Hsp70 and other chaperones. All these make existing anticancer drugs target Hsp70/90 which might be used in AD therapy.
    BioMed Research International 07/2014; 2014(2):239164. DOI:10.1155/2014/239164 · 1.58 Impact Factor
  • Source
    • "Extracellular signal-regulated protein kinase (ERK) is an Hsp90 client protein, and 17-AAG is able to reduce the amount of and aggregation of phosphorylated tau, possibly by inhibiting the action of ERK [36]. 17-AAG is capable of inducing Hsp40 and Hsp70, of which Hsp70 was seen to be able to reduce the level of tau [33,37]. In light of the above evidence, 17-AAG is worth investigating as a therapeutic agent for tauopathies such as FTLD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD), the most common dementia, is characterized by potentially neurotoxic aggregation of Abeta peptide and tau protein, and their deposition as amyloid plaques and neurofibrillary tangles (NFTs). Tau aggregation also occurs in other common neurodegenerative diseases. Frontotemporal dementia (FTD) can be caused by tau mutations that increase the susceptibility of tau to hyperphosphorylation and aggregation, which may cause neuronal dysfunction and deposition of NFTs. 17-allylamino-17-demethoxygeldanamycin (17-AAG) is a potent inhibitor of heat shock protein 90 (Hsp90), a cytosolic chaperone implicated in the proper folding and functions of a repertoire of client proteins. 17-AAG binds to Hsp90 and enhances degradation of Hsp90 client protein. We sought to determine whether 17-AAG can reduce Abeta and tau pathology in the brains of AD and FTD model mice expressing Abeta or P301L mutant tau, respectively. Mice were randomized to receive 25, 5, or 0 mg/kg 17-AAG thrice weekly from age eight to 11 months. Analysis was performed by rotarod test on motor function, on the area occupied by plaques in hippocampus or NFTs in medulla tissue sections, and on mortality. A high dose of 17-AAG tended to decrease NFTs in male mice (p = 0.08). Further studies are required to confirm the effect of 17-AAG in diseases of tau aggregation.
    Translational Neurodegeneration 12/2013; 2(1):24. DOI:10.1186/2047-9158-2-24
  • Source
    • "One phenothiazine, methylene blue (MB; phenothiazine methylthionium chloride), has been involved in multiple clinical trials testing its efficacy for many diseases ranging from psychiatric disorders to cancer [44]. In addition, MB was originally identified as a potent beta-pleated sheet inhibitor [45] and more recently as an Hsp70 inhibitor [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tau is a soluble, microtubule-associated protein known to aberrantly form amyloid-positive aggregates. This pathology is characteristic for more than 15 neuropathies, the most common of which is Alzheimer's disease. Finding therapeutics to reverse or remove this non-native tau state is of great interest; however, at this time only one drug is entering phase III clinical trials for treating tauopathies. Generally, tau manipulation by therapeutics can either directly or indirectly alter tau aggregation and stability. Drugs that bind and change the conformation of tau itself are largely classified as aggregation inhibitors, while drugs that alter the activity of a tau-effector protein fall into several categories, such as kinase inhibitors, microtubule stabilizers, or chaperone modulators. Chaperone inhibitors that have proven effective in tau models include heat shock protein 90 inhibitors, heat shock protein 70 inhibitors and activators, as well as inducers of heat shock proteins. While many of these compounds can alter tau levels and/or aggregation states, it is possible that combining these approaches may produce the most optimal outcome. However, because many of these compounds have multiple off-target effects or poor blood-brain barrier permeability, the development of this synergistic therapeutic strategy presents significant challenges. This review will summarize many of the drugs that have been identified to alter tau biology, with special focus on therapeutics that prevent tau aggregation and regulate chaperone-mediated clearance of tau.
    Alzheimer's Research and Therapy 09/2013; 5(5):41. DOI:10.1186/alzrt207 · 3.98 Impact Factor
Show more